drugset / Trial / NCT04906902
Acalabrutinib in CNSL
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research study is a Phase 1/2 clinical trial testing the safety, tolerance and efficacy of the drug Acalabrutinib for people with recurrent or refractory central nervous system lymphoma (CNSL).
Timeline
- Start
- 2021-08-23
- Primary completion
- 2025-11-06
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | 200 mg | Oral |
| Subject | Acalabrutinib | Small molecule | 300 mg | Oral |
| Subject | Acalabrutinib | Small molecule | 400 mg | Oral |